Neurologic Complications of Immunotherapy

被引:0
|
作者
Schiess, Desi [1 ]
Raj, Karuna [1 ]
Shah, Bhavya [1 ]
Yu, Frank [1 ]
Agarwal, Amit [1 ]
机构
[1] UT Southwestern Med Sch, Dept Radiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
关键词
Immunotherapy; Neurologic Complications of Immunotherapy; Imaging of Neurologic Complications of Immunotherapy; ADVERSE EVENTS;
D O I
10.1097/01.CDR.0000661748.95847.23
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Immunotherapy enhances a patient's own immune system to fight against malignancy and has become increasingly popular during the last decade. Tumor cells can escape destruction by the patient's immune system by overexpression of immunosuppressive molecules such as cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed cell death-1 (PD-1) receptor, and its ligand PD-L1. Immunotherapy agents target these inhibitors and basically reactivate the cytotoxic lymphocytes to destroy the tumor cells. Immunotherapy agents currently are FDA-approved for advanced malignancies including melanoma, Hodgkin lymphoma, head and neck squamous cell carcinoma, non-small cell lung cancer, and renal cell carcinoma. In addition, they have shown beneficial promise in the treatment of other malignancies such as high-grade gliomas.1 As of 2018, the common immune checkpoint blocking antibodies approved by the FDA for immunotherapy include ipilimumab, nivolumab, and pembrolizumab; however, exponential growth of these agents is expected in the next few years when many new agents will receive approval and cover a wider range of malignancies. Considering that immunotherapy seeks to harness the patient's own immune system to fight cancer, increased inflammatory changes are expected. The inflammatory changes may involve the skin, gastrointestinal tract, liver, endocrine, and neurologic systems and together are known as immune-related adverse events (irAEs).
引用
收藏
页码:1 / 7
页数:8
相关论文
共 50 条
  • [1] Neurologic Complications of Cancer Immunotherapy
    Alsalem, Aseel N.
    Scarffe, Leslie A.
    Briemberg, Hannah R.
    Aaroe, Ashley E.
    Harrison, Rebecca A.
    CURRENT ONCOLOGY, 2023, 30 (06) : 5876 - 5897
  • [2] Neurologic Toxicities of Immunotherapy
    Harrison, Rebecca A.
    Majd, Nazanin K.
    Tummala, Sudhakar
    de Groot, John F.
    IMMUNOTHERAPY, 4TH EDITION, 2021, 1342 : 417 - 429
  • [3] Neurologic complications of immunization
    Bate, JF
    JOURNAL OF CHILD NEUROLOGY, 2004, 19 (06) : 405 - 412
  • [4] NEUROLOGIC COMPLICATIONS OF MIGRAINE
    CROWELL, GF
    CARLIN, L
    BILLER, J
    AMERICAN FAMILY PHYSICIAN, 1982, 26 (04) : 139 - 148
  • [5] NEUROLOGIC COMPLICATIONS OF CIGUATERA
    BAGNIS, RA
    BRONSTEIN, JA
    JOUFFE, G
    FORESTIER, R
    MEUNIER, JL
    LEJAN, J
    BRULEFER, D
    PARC, F
    TETARIA, C
    BULLETIN DE LA SOCIETE DE PATHOLOGIE EXOTIQUE, 1977, 70 (01): : 89 - 93
  • [6] Neurologic complications of aids
    Geraci, AP
    Di Rocco, A
    Simpson, DM
    NEUROLOGIST, 2001, 7 (02) : 82 - 97
  • [7] THE NEUROLOGIC COMPLICATIONS OF CHICKENPOX
    ECHENNE, B
    ASTRUC, J
    BRUNEL, D
    PEDIATRIE, 1981, 36 (07): : 509 - 516
  • [8] NEUROLOGIC COMPLICATIONS IN AIDS
    SCHWENDEMANN, G
    ZEITSCHRIFT FUR HAUTKRANKHEITEN H&G, 1988, 63 (05): : 357 - &
  • [9] Neurologic Complications and Treatment
    Welch, Kevin C.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2015, 48 (05) : 769 - +
  • [10] NEUROLOGIC COMPLICATIONS IN GALACTOSEMIA
    KOCH, TK
    SCHMIDT, KA
    WAGSTAFF, JE
    NG, WG
    PACKMAN, S
    PEDIATRIC NEUROLOGY, 1992, 8 (03) : 217 - 220